GSK and CureVac will together receive $740 million, as well as royalties on sales of COVID-19 vaccines in the US ...

After BioNTech’s acquisition of CureVac closes, BioNTech will pay GSK another $130 million and a 1% royalty on rest-of-world ...

Virus-based treatments are already approved to treat several types of cancer, and combining them with bacteria could make ...

Pfizer (PFE) stock and BioNTech (BNTX) stock in focus as FDA may not renew the authorization for their pediatric COVID shot. Read more here.

On August 1, 2025, a UK Court of Appeal upheld the validity of Moderna’s European Patent No. 3,590,949 (“EP’949”) in a dispute with Pfizer ...

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

COVID-19 activity is rising in much of the country. Data shows overall respiratory virus spread is very low in the U.S.

NasdaqGS:BNTX 1 Year Share Price vs Fair Value Explore BioNTech's Fair Values from the Community and select ...

BioNTech SE is currently sponsoring a clinical study titled ‘A Phase I/II, Multi-site, Open-label, Two-part Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of BNT323 in Combination With ...

Showing that his loyalty to his own anti-vax mentality is greater than his loyalty to President Donald Trump, Robert F. Kennedy Jr., the dangerous quack atop the Department of Health and Human ...

Parents in the United States who want to vaccinate their young children against Covid-19 this fall may face a growing set of ...

They’re turning their backs on a technology thought to have saved millions of lives—with the potential to save many more.